
Sign up to save your podcasts
Or


Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.
By Nate Geraci4.5
6464 ratings
Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.

518 Listeners

2,175 Listeners

1,993 Listeners

943 Listeners

105 Listeners

288 Listeners

797 Listeners

2,020 Listeners

196 Listeners

2,145 Listeners

934 Listeners

83 Listeners

84 Listeners

114 Listeners

830 Listeners